Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Invictus MD Strategies's Sloan Ratio for the quarter that ended in Oct. 2019 was -4.30%.
As of Oct. 2019, Invictus MD Strategies has a Sloan Ratio of -4.30%, indicating the company is in the safe zone and there is no funny business with accruals.
Invictus MD Strategies Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Invictus MD Strategies's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invictus MD Strategies's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Invictus MD Strategies's Sloan Ratio % falls into.
Invictus MD Strategies Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Invictus MD Strategies's Sloan Ratio for the fiscal year that ended in Jan. 2019 is calculated as
Invictus MD Strategies's Net Income for the trailing twelve months (TTM) ended in Oct. 2019 was -10.683 (Jan. 2019 ) + -3.47 (Apr. 2019 ) + -9.419 (Jul. 2019 ) + -4.998 (Oct. 2019 ) = $-28.57 Mil.
Invictus MD Strategies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Oct. 2019 was -5.662 (Jan. 2019 ) + -2.811 (Apr. 2019 ) + -1.014 (Jul. 2019 ) + -1.358 (Oct. 2019 ) = $-10.85 Mil.
Invictus MD Strategies's Cash Flow from Investing for the trailing twelve months (TTM) ended in Oct. 2019 was -9.673 (Jan. 2019 ) + -3.403 (Apr. 2019 ) + -0.399 (Jul. 2019 ) + -0.179 (Oct. 2019 ) = $-13.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invictus MD Strategies (OTCPK:IVITF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Oct. 2019, Invictus MD Strategies has a Sloan Ratio of -4.30%, indicating the company is in the safe zone and there is no funny business with accruals.
Invictus MD Strategies Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Invictus MD Strategies's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Invictus MD Strategies (Invictus MD Strategies) Business Description
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IVITF has been successfully added to your 